驱动基因阳性晚期非小细胞肺癌靶向治疗

doi:10.3760/cma.j.cn371439-20200911-00047

摘要/Abstract

摘要：

近年来,分子靶向治疗有效改善了驱动基因阳性晚期非小细胞肺癌(NSCLC)患者的预后,其中,针对存在人体表皮生长因子受体基因突变、棘皮动物微管相关样蛋白4-间变性淋巴瘤激酶融合基因、ROS1基因重排等的NSCLC患者,疗效尤为显著。对于驱动基因阳性晚期NSCLC患者,靶向治疗药物的选择尤为重要。

关键词: 癌, 非小细胞肺, 分子靶向治疗, 驱动基因

Abstract:

In recent years, molecular targeted therapy has effectively improved the prognosis of advanced non-small cell lung cancer (NSCLC) patients with driver gene-positive, of which the efficacy is particularly significant for NSCLC patients with human epidermal growth factor receptor gene mutation, echinoderm microtubule-associated protein-4-anaplastic lymphoma kinase fusion gene, ROS1 gene rearrangement, etc. The selection of targeted therapy drugs is particularly important for advanced NSCLC patients with positive driver genes.

Key words: Carcinoma, non-small cell lung, Molecular targeted therapy, Driver gene

杨晨光, 徐志巧. 驱动基因阳性晚期非小细胞肺癌靶向治疗[J]. 国际肿瘤学杂志, 2021, 48(4): 235-240.

Yang Chenguang, Xu Zhiqiao. Targeted therapy for advanced non-small cell lung cancer with driver gene-positive[J]. Journal of International Oncology, 2021, 48(4): 235-240.

参考文献 43

[1]	Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer[J]. Ann Glob Health, 2019, 85(1):8. DOI: 10.5334/aogh.2419.
[2]	Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689):446-454. DOI: 10.1038/nature25183. doi: 10.1038/nature25183 pmid: 29364287
[3]	Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs[J]. JAMA, 2014, 311(19):1998-2006. DOI: 10.1001/jama.2014.3741. doi: 10.1001/jama.2014.3741
[4]	Ettinger DS, Wood DE, Aggarwal C, et al. NCCN guidelines insights: non-small cell lung cancer, version 1.2020[J]. J Natl Compr Canc Netw, 2019, 17(12):1464-1472. DOI: 10.6004/jnccn.2019.0059. doi: 10.6004/jnccn.2019.0059 pmid: 31805526
[5]	Yamaoka T, Kusumoto S, Ando K, et al. Receptor tyrosine kinase-targeted cancer therapy[J]. Int J Mol Sci, 2018, 19(11):3491. DOI: 10.3390/ijms19113491. doi: 10.3390/ijms19113491
[6]	Wang J, Wang B, Chu H, et al. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations[J]. Onco Targets Ther, 2016, 9:3711-3726. DOI: 10.2147/OTT.S106399.
[7]	Wu YL, Saijo N, Thongprasert S, et al. Efficacy according to blind independent central review: post-hoc analyses from the phase Ⅲ, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC[J]. Lung Cancer, 2017, 104:119-125. DOI: 10.1016/j.lungcan.2016.11.022. doi: 10.1016/j.lungcan.2016.11.022
[8]	Zhao Y, Liu J, Cai X, et al. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis[J]. BMJ, 2019, 367:l5460. DOI: 10.1136/bmj.l5460.
[9]	Kelly RJ, Shepherd FA, Krivoshik A, et al. A phase Ⅲ, rando-mized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage ⅢB/Ⅳ non-small-cell lung cancer[J]. Ann Oncol, 2019, 30(7):1127-1133. DOI: 10.1093/annonc/mdz128. doi: 10.1093/annonc/mdz128
[10]	张钰, 周建国, 马虎. 非小细胞肺癌分子靶向治疗及其耐药[J]. 国际肿瘤学杂志, 2016, 43(1):45-48. DOI: 10.3760/cma.j.issn.1673-422X.2016.01.013.
[11]	Wu SG, Liu YN, Tsai MF, et al. The mechanism of acquired resis-tance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients[J]. Oncotarget, 2016, 7(11):12404-12413. DOI: 10.18632/oncotarget.7189. doi: 10.18632/oncotarget.v7i11
[12]	Park K, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial[J]. Lancet Oncol, 2016, 17(5):577-589. DOI: 10.1016/S1470-2045(16)30033-X. doi: 10.1016/S1470-2045(16)30033-X
[13]	Wu YL, Cheng Y, Zhou XD, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation positive non-small-cell lung cancer (ARCHER1050): a randomised, open-label, phase 3 trial[J]. Lancent Oncol, 2017, 18(11):1454-1466. DOI: 10.1016/S1470-2045(17)30608-3.
[14]	Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer[J]. Br J Cancer, 2019, 121(9):725-737. DOI: 10.1038/s41416-019-0573-8. doi: 10.1038/s41416-019-0573-8
[15]	Jänne PA, Yang J CH, Kim DW, et al. AZD9291 in EGFR inhi-bitor resistance non-small-cell lung cancer[J]. N Eng J Med, 2015, 372(18):1689-1699. DOI: 10.1056/NEJMoa1411817. doi: 10.1056/NEJMoa1411817
[16]	Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M positive advanced non-small-cell lung cancer: AURA study phase Ⅱ extension component[J]. J Clin Oncol, 2017, 35(12):1288-1296. DOI: 10.1200/JCO.2016.70.3223. doi: 10.1200/JCO.2016.70.3223
[17]	Gourd E. Overall survival with osimertinib in untreated NSCLC[J]. Lancet Oncol, 2020, 21(1): e15. DOI: 10.1016/S1470-2045(19)30778-8. doi: 10.1016/S1470-2045(19)30778-8
[18]	Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2):113-125. DOI: 10.1056/NEJMoa1713137. doi: 10.1056/NEJMoa1713137
[19]	Cho JH, Lim SH, An HJ, et al. Osimertinib for patients with non-small-cell lung cancer harboring uncommom EGFR mutations: a multicencet, open-label, phase Ⅱ trial (KCSG-LU15-09)[J]. J Clin Oncol, 2020, 38(5):488-495. DOI: 10.1200/JCO.19.00931.
[20]	Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer[J]. J Clin Oncol, 2018, 36(9):841-849. DOI: 10.1200/JCO.2017.74.7576. doi: 10.1200/JCO.2017.74.7576
[21]	Kannan S, Venkatachalam G, Lim HH, et al. Conformational landscape of the epidermal growth factor receptor kinase reveals a mutant specific allosteric pocket[J]. Chem Sci, 2018, 9(23):5212-5222. DOI: 10.1039/c8sc01262h. doi: 10.1039/C8SC01262H
[22]	Jia Y, Yun CH, Park E, et al. Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant selective allosteric inhibitors[J]. Nature, 2016, 534(7605):129-132. DOI: 10.1038/nature17960. doi: 10.1038/nature17960
[23]	Gridelli C, Peters S, Sgambato A, et al. ALK inhibitors in the treatment of advanced NSCLC[J]. Cancer Treat Rev, 2014, 40(2):300-306. DOI: 10.1016/j.ctrv.2013.07.002. doi: 10.1016/j.ctrv.2013.07.002
[24]	Nishio M, Kim DW, Wu YL, et al. Crizotinib versus chemotherapy in Asian patients with advanced ALK-positive non-small cell lung cancer[J]. Cancer Res Treat, 2018, 50(3):691-700. DOI: 10.4143/crt.2017.280. doi: 10.4143/crt.2017.280
[25]	Wu YL, Lu S, Lu Y, et al. Results of PROFILE 1029, a phase Ⅲ comparison of first-line crizotinib versus chemotherapy in east Asian patients with ALK-positive advanced non-small cell lung cancer[J]. J Thorac Oncol, 2018, 13(10):1539-1548. DOI: 10.1016/j.jtho.2018.06.012. doi: 10.1016/j.jtho.2018.06.012
[26]	Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(9):829-838. DOI: 10.1056/NEJMoa1704795. doi: 10.1056/NEJMoa1704795
[27]	Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study[J]. Lancet Respir Med, 2019, 7(5):437-446. DOI: 10.1016/S2213-2600(19)30053-0. doi: 10.1016/S2213-2600(19)30053-0
[28]	Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study[J]. Ann Oncol, 2020, 31(8):1056-1064. DOI: 10.1016/j.annonc.2020.04.478. doi: 10.1016/j.annonc.2020.04.478
[29]	Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in alk-positive non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21):2027-2039. DOI: 10.1056/NEJMoa1810171. doi: 10.1056/NEJMoa1810171
[30]	Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study[J]. Lancet, 2017, 389(10072):917-929. DOI: 10.1016/S0140-6736(17)30123-X. doi: 10.1016/S0140-6736(17)30123-X
[31]	Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models[J]. Cancer Cell, 2015, 28(1):70-81. DOI: 10.1016/j.ccell.2015.05.010. doi: 10.1016/j.ccell.2015.05.010
[32]	Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial[J]. Lancet Oncol, 2017, 18(12):1590-1599. DOI: 10.1016/S1470-2045(17)30680-0. doi: 10.1016/S1470-2045(17)30680-0
[33]	Schrank Z, Chhabra G, Lin L, et al. Current molecular-targeted therapies in NSCLC and their mechanism of resistance[J]. Cancers (Basel), 2018, 10(7):224. DOI: 10.3390/cancers10070224. doi: 10.3390/cancers10070224
[34]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI: 10.3322/caac.21338. doi: 10.3322/caac.21338
[35]	金瑶, 翁一鸣, 胥泽玺, 等. ROS1阳性非小细胞肺癌靶向治疗的研究进展[J]. 国际肿瘤学杂志, 2019, 46(12):745-749. DOI: 10.3760/cma.j.issn.1673-422X.2019.12.008.
[36]	Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer[J]. N Engl J Med, 2014, 371(21):1963-1971. DOI: 10.1056/NEJMoa1406766. doi: 10.1056/NEJMoa1406766
[37]	Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001[J]. Ann Oncol, 2019, 30(7):1121-1126. DOI: 10.1093/annonc/mdz131. doi: 10.1093/annonc/mdz131
[38]	Wu YL, Yang JC, Kim DW, et al. Phase Ⅱ study of crizotinib in east Asian patients with ROS1-positive advanced non-small-cell lung cancer[J]. J Clin Oncol, 2018, 36(14):1405-1411. DOI: 10.1200/JCO.2017.75.5587. doi: 10.1200/JCO.2017.75.5587
[39]	Juan O, Popat S. Crizotinib for ROS1 patients: one small step in biomarker testing, one giant leap for advanced NSCLC patients[J]. Lung Cancer, 2017, 104:131-133. DOI: 10.1016/j.lungcan.2016.11.007. doi: 10.1016/j.lungcan.2016.11.007
[40]	Lim SM, Kim HR, Lee JS, et al. Open-label, multicenter, phase Ⅱ study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement[J]. J Clin Oncol, 2017, 35(23):2613-2618. DOI: 10.1200/JCO.2016.71.3701. doi: 10.1200/JCO.2016.71.3701
[41]	Davare MA, Vellore NA, Wagner JP, et al. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors[J]. Proc Natl Acad Sci U S A, 2015, 112(39): E5381-E5390. DOI: 10.1073/pnas.1515281112. doi: 10.1073/pnas.1515281112
[42]	Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1 positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial[J]. Lancet Oncol, 2019, 20(12):1691-1701. DOI: 10.1016/S1470-2045(19)30655-2. doi: 10.1016/S1470-2045(19)30655-2
[43]	Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials[J]. Lancet Oncol, 2020, 21(2):261-270. DOI: 10.1016/S1470-2045(19)30690-4. doi: 10.1016/S1470-2045(19)30690-4